Silver Book Fact

Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.

Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield. Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform. Diabetes Care. 1994; 17(8): 909-17. http://care.diabetesjournals.org/cgi/content/abstract/17/8/909

Reference

Title
Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform
Publication
Diabetes Care
Publication Date
1994
Authors
Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield
Volume & Issue
Volume 17, Issue 8
Pages
909-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.  
  • Laser treatment and vitrectomy reduce the risk of blindness in patients with severe diabetic retinopathy by 90%.  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • Intensive Glycemic Control in People with Diabetes
    Intensive glycemic control in diabetics reduced their: Adjusted mean risk of DR by 76% Risk of progression by 54% Rates of laser surgery by 56% Risk of DME by 23%